"Pharmaceutical Speed Reader" local health insurance 3 years of retirement varieties announced spread AZ want to buy Gilead

3-year digestion principle of health insurance supplementary drugs in Chongqing; Net-a-Porter AstraZeneca wants to acquire Gilead; China's first new crown neutralizing antibody launch clinical trial; Guangshengtang anti-hepatitis b virus drug ramifenine tablets pass consistency evaluation; Roche TIGIT monotonics declared clinical in China ...
Today, the Chongqing Municipal Health Insurance Bureau issued "on the gradual digestion of the local supplement of the list of health insurance Class B drugs in Chongqing." In the "Publicity", Chongqing City issued the local supplement of the three-year digestion of the drugThe digestive schedule is determined as: the first year of digestion of drugs, from January 1, 2021 to stop medical insurance reimbursement, the second year of digestion of drugs, from January 1, 2022 to stop medical insurance reimbursement, the third year of the digestion of drugs, from July 1, 2022 to stop medical insurance reimbursement(Chongqing Municipal Medical Insurance Bureau)Shenzhen Central Hospital announced the 2020 phase-out of non-national basic drug varieties catalog, including a total of 148 varieties, including some clinically commonly used large varietiesAstraZeneca is in contact with Gilead Sciences about a possible merger that, if successful, would be the largest medical deal in history, involving $96 billion, according to people familiar with the matterIf the merger succeeds, it would surpass the $74 billion merger between 100-eleven and Newage in 2019 and the $63 billion merger between AbbVie and AlK(Sina Pharmaceutical News)8, Consino Bio noon issued a clarification announcement, the company noted the stock price fluctuations and some media reports about the restructuring of the new coronavirus vaccine (Ad5-nCoV) production in GuizhouAd5-nCoV is jointly developed and owned by the Company and the Institute of Bioengineering at the Institute of Military Medicine of the Academy of Military MedicineThe Company has the full right to produce and commercialize Ad5-nCoV, and according to the Drug Administration Law of the People's Republic of China and the Vaccine Administration Law of the People's Republic of China, vaccine producers shall have sufficient capacity and qualifications to produce vaccines and shall be subject to the supervision of the State Drug Administration(Sina Pharmaceutical News)Boginger Ingham's anti-pulmonary fibrosis treatment drug Vigat (English name: Ofev, generic name: nidanab softgel seis) has been approved for nMPA, becoming the first and only drug currently used for systemic sclerosis-related interstitial pulmonary diseaseAt present, Vegat has been approved in more than 70 countries and regions for the treatment of isopulmonal fibrosis, has been approved in 15 countries for the treatment of systemic sclerosis-related interstitial pulmonary disease(Sina Pharmaceutical News)Novartis recently announced that the full results of the Study of Argonii IIIB for the Treatment of Asthma by Enerzair Breezhaler (QVM149, IND/GLY/MF) of single-inhaler triple therapy have been published in Respiratory Medicine The results showed that the daily high dose of single-inhaler and the medium dose of Enerzair Breezhaler in improving the quality of life of patients with uncontrolled asthma, not less effective than two daily doses of tamoxero/propylene fluatelaxandand and a daily tinta-sniffing combination therapy (Sina Pharmaceutical News) Junshi Bio announced on the 7th that its recombinant all-human anti-SARS-CoV-2 monoclonal antibody injection, jointly developed with the Institute of Microbiology of the Chinese Academy of Sciences, was approved to enter phase I clinical trial phase, and completed the first case of subject administration at Huashan Hospital affiliated with Fudan University (Sina Pharmaceutical News) 8, the State Drug Administration announced that the recent review and approval of Edwards Lifesciences LLC production of innovative products "through the catheter aortic valve system" registration The drug regulatory department will strengthen post-marketing supervision of the product to protect the safety of patients (Sina Pharmaceutical News) Blueprint Medicines presents the latest results of the company's precision protein kinase inhibitor avapritinib at the 2020 European Society of Allergy and Clinical Immunology meeting, the latest results in the treatment of patients with inert systemic hypertrophy (SM) The results showed that avapritinib was able to significantly improve skin symptoms in SM patients 8, Roche filed a clinical application for Tiragolumab injectionin in China to be accepted by CDE, a TIGIT monotonic At present, Roche Tecentriq has been approved in China for the first-line treatment of a wide range of small cell lung cancer, and submitted Tecentriq joint bevalzumab first-line treatment of liver cancer listing application (Pharmarubik Cube) on the 8th, Mersha Dong-Tmovir injections/ tablets were approved clinically in China for allogeneic hematopoietic stem cell transplantation (HSCT) sero-positive adult recipients of the (R-) prevention of CMV reactivation and disease The drug, which was approved by the FDA in 2017/11/8, is the first drug in the United States in nearly 15 years to be approved to treat cytomegalovirus (Pharmaceutical Rubik's Cube) 8, Guangshengtang issued a notice that the company recently received the Approval of the State Drug Administration issued on the Ramifdin tablets of the "drug supplement application approval", the company Ramifdin tablets (He Ganding) through the quality of generic drugs and efficacy consistency evaluation Company Ramifdin (He Ganding) is the only selected national "major new drug creation" science and technology major special "12th Five-Year Plan" implementation plan of the domestic Ramifdin varieties (Sina Pharmaceutical News)